Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways by Zilka, Norbert et al.
REVIEW Open Access
Who fans the flames of Alzheimer’s disease
brains? Misfolded tau on the crossroad of
neurodegenerative and inflammatory pathways
Norbert Zilka
1,2, Zuzana Kazmerova
1, Santosh Jadhav
1, Peter Neradil
1, Aladar Madari
3, Dominika Obetkova
1,
Ondrej Bugos
1 and Michal Novak
1,2*
Abstract
Neurodegeneration, induced by misfolded tau protein, and neuroinflammation, driven by glial cells, represent the
salient features of Alzheimer’s disease (AD) and related human tauopathies. While tau neurodegeneration
significantly correlates with disease progression, brain inflammation seems to be an important factor in regulating
the resistance or susceptibility to AD neurodegeneration. Previously, it has been shown that there is a reciprocal
relationship between the local inflammatory response and neurofibrillary lesions. Numerous independent studies
have reported that inflammatory responses may contribute to the development of tau pathology and thus
accelerate the course of disease. It has been shown that various cytokines can significantly affect the functional
and structural properties of intracellular tau. Notwithstanding, anti-inflammatory approaches have not unequivocally
demonstrated that inhibition of the brain immune response can lead to reduction of neurofibrillary lesions. On the
other hand, our recent data show that misfolded tau could represent a trigger for microglial activation, suggesting
the dual role of misfolded tau in the Alzheimer’s disease inflammatory cascade. On the basis of current knowledge,
we can conclude that misfolded tau is located at the crossroad of the neurodegenerative and neuroinflammatory
pathways. Thus disease-modified tau represents an important target for potential therapeutic strategies for patients
with Alzheimer’s disease.
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Neurodegenerative niche in the ocean of the
brain inflammation
Alzheimer’s disease (AD), the major cause of dementia,
is characterized by the aberrant folding of the protein
tau, leading to its intracellular and extracellular accumu-
lation and to b-amyloidosis seen as extracellular deposits
of b-amyloid (Ab) in the brain parenchyma and around
cerebral blood vessels [1-8]. Although it is well-docu-
mented that Ab deposition is considered to be an
important inducer of the chronic inflammatory response
driven by activated microglia and astrocytes [9-12], little
is known about the role of misfolded tau in the neuroin-
flammatory cascade. In AD, the pathological lesions of
misfolded tau are present as intracellular and extracellu-
lar neurofibrillary tangles, neuropil threads and neuritic
plaques [6,7]. Interestingly, several independent studies
have revealed that the regional distribution and load of
neurofibrillary lesions parallel the distribution of reactive
microglia in AD [13,14]. In an extensive histopathologi-
cal study published by Irina Alafuzoff’sg r o u p ,i tw a s
shown that ApoE genotype significantly influenced the
linkage between neurofibrillary tangles (NFTs) and acti-
vated microglia. Furthermore, the authors clearly
demonstrated that microglial upregulation of major his-
tocompatibility complex class II antigen (HLA-DR)
increased the duration of AD and correlated with NFT
counts in sporadic cases, but not in familial ones [15].
Apparently, activated microglia were frequently pre-
sent in the proximity of NFTs at early [16] and later
stages of tangle formation [14,17,18] (Figures 1A and
1B). Sheng et al. showed that the number of IL-1a-posi-
tive microglia and S100b-positive astrocytes progres-
sively increased with NFT load, suggesting that both
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any medium, provided the original work is properly cited.Figure 1 Activated microglia are localized in brain areas affected by neurofibrillary tangles. Reactive microglia, stained by Iba1 antibody
(red colour), are distributed throughout the brain regions affected by neurofibrillary lesions immunolabelled with AT8 (antibody recognizing
phospho-tau, green colour) and DC11 (antibody recognizing Alzheimer’s disease (AD)-specific misfolded tau, green colour). Activated microglia
are surrounding tangle-bearing neurons in the hippocampus of an AD patient (A) and (B) and in the cortices of transgenic rats expressing
truncated tau protein (C) and (D). Scale bars: 100 μm.
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and astroglia, are involved in the immune response tar-
geting tau pathology [16]. It is noteworthy that, in the
late stages of tangle development, astrocytes and micro-
glia infiltrate extracellular “ghost” tangles and may con-
tribute to the degradation of tau filaments [17,19].
Likewise, the complement proteins C1q, C3d and C4d
were found to colocalize with dystrophic neurites, neu-
ropil threads and tangle-bearing neurons. Similarly, an
antibody recognizing the C5b-9 membrane attack com-
plex stained dystrophic neurites and many tangle-bear-
ing neurons [20,21].
It has been clearly demonstrated that microglial activa-
tion also correlates with tau lesions in other human tauo-
pathies, such as Guam parkinsonism dementia, Pick’s
disease, progressive supranuclear palsy and corticobasal
degeneration [22-27]. The activation of microglia linked to
tau deposition has been well-documented in various trans-
genic rodent models expressing human mutant tau protein
P301S [28,29], R406W [30], P301L [31] or disease-modi-
fied, truncated tau protein [32,33]. We have shown that
transgenic rat lines expressing human truncated tau devel-
oped extensive neurofibrillary degeneration, either in the
cortex [34] or in the brainstem [35]. The neurofibrillary
pathology in the transgenic rat brain fulfils criteria for
human NFTs. Importantly, the load of NFTs positively
correlated with reactive microglia (Figures 1C and 1D)
[34]. Occasionally, activated microglia were closely
attached to tangle-bearing neurons (Figure 2), suggesting
direct causative interconnection between tangles and reac-
tive microglia [32]. Although there is convincing evidence
that diseased, modified tau and neuroinflammation are
closely linked, the precise relationship remains unclear.
Immunosuppression could attenuate tau
pathology
The concept based on the premise that anti-inflamma-
tory therapy may prevent or retard the development of
AD originated with the discovery that neuroinflamma-
tion strongly correlates with AD and that it is asso-
ciated with senile plaque pathology and NFTs [36,37].
Moreover, epidemiological studies have indicated that
nonsteroidal anti-inflammatory drugs (NSAIDs) lower
the risk of developing AD [38,39]. In accord with these
findings, several drugs, such as the nonselective or
COX2-selective NSAIDs and glucocorticoid steroids,
were studied to determine if they offer any benefits to
AD patients. However, randomized controlled trials
assessing COX2 inhibitors (rofecoxib and celecoxib),
COX1 and COX2 inhibitors (naproxen and indometha-
cin) and glucocorticoids (prednisone) failed to demon-
strate any beneficial effect on cognition, behaviour or
activities of daily living among AD patients [37,40-43].
Furthermore, NSAIDs were not associated with reduc-
tions in the load of neuritic plaques (NPs) or NFTs in
human AD brain. On the contrary, one study showed
that heavy NSAID use was associated with a significant
increase in NPs [44]. In contrast, it has been shown
that the use of corticosteroids significantly decreased
the density of NPs and NFTs in the entorhinal cor-
tices, hippocampi and amygdalae of AD patients [45].
Similarly, immunosuppressive treatment of young
transgenic mice expressing mutant tau P301S attenu-
ated tau pathology and increased lifespan. This animal
study revealed that targeted inhibition of the inflam-
matory response can reduce tau pathology and amelio-
rate disease progression [29].
Figure 2 Colocalization of clustered microglia and neurofibrillary tangles in transgenic rat brain. Neurofibrillary tangles (NFTs) were
detected with the monoclonal antibody AT180, recognizing tau protein phosphorylated at Thr231 and Ser235 (A), respectively. Activated
microglia were stained with the polyclonal antibody Iba1, specific for ionized calcium-binding adaptor molecule 1 (B). Confocal study showed
that some NFTs colocalized with clusters of activated microglia (C). Scale bars: 100 μm.
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neuroinflammation?
Whether microglia activation precedes neurodegenera-
tion remains an issue of debate. Several independent
studies have shown that neurofibrillary pathology and
reactive microglia display the same distribution pattern
in AD. The presence of reactive microglia in brain areas
affected by neurodegeneration indicates that NFT
pathology can drive neuroinflammation. However, some
authors have argued that reactive microglia precede tan-
gle formation and thus can establish a template for the
development of neurofibrillary degeneration. Sheffield
and colleagues [14] showed that microglia occupied the
greatest area in periallocortex/allocortex (hippocampus
CA1, entorhinal cortex and parasubiculum), a lesser
area in association cortex (superior temporal gyrus and
orbitofrontal cortex) and the smallest area in primary
visual and motor cortex in AD and in controls without
AD [14]. Similar findings were described in a mouse
model expressing mutated tau P301S, where microglial
activation preceded tangle formation [29]. This is only
one side of the story; another side points towards age-
related structural deterioration of microglial cells that
may even precede tangle formation. Wolfgang Streit
demonstrated that dystrophic rather than activated
microglia correlated with tau lesions [46-48]. Structural
and functional impairment of microglial cells may signif-
icantly affect the bidirectional communication between
tangle-bearing neurons and dystrophic microglial cells.
Furthermore, degeneration of microglia would necessa-
rily be associated with a loss of their potential neuropro-
tective properties. In conclusion, a breakdown of
communication between microglia and neurons could
contribute to the onset of AD [46-48].
Cytokine storm can finely tune tau
neurodegenerative metamorphosis
Placing cytokine responses upstream in the cascade of
deleterious events that lead to tau neurodegeneration
has opened new avenues in AD research. Many inde-
pendent in vivo and ex vivo studies provide compelling
evidence that cytokines can significantly influence the
pathological modifications of tau protein. This issue was
brought to light by the landmark study of Li et al. [49],
who showed that reactive microglia producing proin-
flammatory cytokines such as IL-1 induced an increase
in tau phosphorylation in primary cortical neurons. This
effect was mediated via the p38 mitogen-activated pro-
tein kinase (MAPK) pathways. Similar studies support-
ing this notion showed that either nitric oxide (NO) or
IL-6 can promote tau phosphorylation inside neuronal
cells [50,51]. Recently, Lee et al. [52] reported that injec-
tions of lipopolysaccharide (LPS) into the frontal cor-
tices and hippocampi of transgenic mice rTg4510
expressing human mutant tau P301L induced significant
activation of CD45 immunoreactive microglia and
increased tau phosphorylation at Ser199/202 and
Ser396; however, LPS did not affect the load of silver-
positive NFTs. Consistent with these findings, a subse-
quent study using a 3 × Tg-AD model harbouring
PS1M146V +A P P KM670/671NL +t a u P301L mutations
revealed increased phosphorylation of tau (p231/235 and
p202/205) in the hippocampus [53]. LPS can induce
microglial activation and promote hyperphosphorylation
of endogenous tau in wild-type mice as well. Increased
phospho-tau levels were dependent upon TLR-4 and IL-
1 signalling. Moreover, tau phosphorylation was further
enhanced in mice lacking the microglia-specific fractalk-
ine receptor (CX3CR1) [54]. Interestingly, gene delivery
of the proinflammatory cytokine TNF-a into the brains
of 3 × Tg-AD mice induced microglial activation and
enhanced intracellular levels of hyperphosphorylated tau
[55]. Additionally, a lifetime-based Förster energy reso-
nance transfer (FRET) microscopy study revealed that
either activated microglia producing TNF-a or the glia-
derived cytokine TNF-a alone were able to induce the
accumulation of tau preferentially in neurites [56].
These results strongly suggest that cytokines can signifi-
cantly modify tau phosphorylation, but have limited
impact on tangle formation.
Recent data cast a new light on the role of fractalkine
as a key regulator of tangle development. Bhaskar and
colleagues [54] showed that transgenic mice lacking
CX3CR1 and expressing human tau isoforms had mark-
edly increased numbers of tangle-bearing neurons. This
contrasts with a previously published report where the
same research group showed that CX3CR1 deficiency
led to a reduction of Ab deposits [57]. It is important to
stress, however, that amyloid lesions are located in the
extracellular space and that therefore a different
mechanism of microglial action could be involved in the
degradation of amyloid deposits [57].
On the basis of the data reported so far, it is tempting
to hypothesize that molecular dialogue between neuro-
nal cells and microglia can significantly influence neuro-
nal vulnerability to tangle formation. Also on the basis
of these data, one could propose that the proinflamma-
tory immune response can amplify tau phosphorylation,
which can accelerate tangle formation.
Genetic background modifies the
neuroinflammatory response to tau
neurodegeneration
Numerous epidemiological studies have demonstrated that
genetic background modifies the onset and progression of
AD and related neurodegenerative disorders. Studies using
amyloid mouse models of AD have demonstrated the
importance of genetic background for the transgenic
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on survival, behaviour, amyloid levels and plaque burden
in the brains of amyloid transgenic mice has been
observed [58]. To identify genetic modifiers on the tau
neurodegenerative and neuroinflammatory cascades, we
used transgenic lines expressing human truncated tau pro-
tein in either the spontaneously hypertensive rat (SHR) or
on the Wistar-Kyoto (WKY) genetic background [33]. The
SHR background was chosen for its propensity to develop
major risk factors for AD, such as hypertension, insulin
Figure 3 Functional plasticity of microglial cells in transgenic rat brain expressing human truncated tau protein. Intraneuronal
expression of human truncated tau induces neurofibrillary degeneration. Injured neurons drive resting microglia to become reactive microglia
that transform into brain phagocytic microglia: brain macrophages. At this stage, microglia lose contact inhibition and begin to fuse with each
other, forming small clusters. Morphological activation of microglia is accompanied with upregulation of several immunological markers,
including integrins CD11a, CD11b, CD11c and CD18; lymphocytic antigen CD4; leukocyte common antigen CD45; and lysosomal glycoprotein
CD68 (colour dots). In the late stage of neurodegeneration, bloodborne leukocytes (mainly monocytes and partially dendritic cells) infiltrate the
brain parenchyma and participate in the brain’s immune response.
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tau neurodegeneration can induce inflammatory responses
mediated by reactive microglia [32,33]. Activated microglia
underwent a transformation from resting to reactive and
phagocytic states accompanied by upregulation of several
immunologically important molecules, including CD11a,
CD11b, CD11c, CD18, CD4, CD45 and CD68. Reactive
microglia were frequently distributed around axonal
lesions and in close proximity to NFTs. Simultaneously,
the innate immune brain response promoted the influx of
Figure 4 Tau neuroinflammatory cascade. In early stages of tau structural metamorphosis, some proinflammatory cytokines (IL-1, IL6 and TNF-
a) and chemokines (fractalkine) can modify tau phosphorylation patterns and thus change the structure and function of tau protein. The major
sources of proinflammatory cytokines are activated microglia and astrocytes. Glial cells can be activated by different inducers, including
misfolded tau protein. At this stage, however, the phosphorylated tau protein would not necessarily aggregate into the filamentous structures
(A). In later stages, when misfolded hyperphosphorylated tau proteins form mature NFTs, inflammation could either accelerate or modify tangle
formation. Several components of the brain’s immune system, including cytokines and proteins of the complement pathway, have been shown
to be involved in the molecular dialogue between activated glial cells and tangle-bearing neurons (B).
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dendritic cells) into the brain parenchyma (Figure 3) [32].
The WKY rats, which were used as normotensive controls,
also developed neurofibrillary degeneration accompanied
by neuroinflammation. Moreover, they displayed signifi-
cantly lower final NFT loads than their SHR transgenic
counterparts. We also observed that microglial responses
showed a striking difference between transgenic lines. In
SHR transgenic rats, a limited number of microglia (less
than 2%) expressed major histocompatibility complex
class II (MHCII) molecules, despite having a robust pha-
gocytic phenotype. In contrast, almost 20% of the micro-
glia expressed MHCII molecules in WKY transgenic rat
brain. Moreover, they displayed a considerably lower
extent of phagocytic morphology [33]. These findings sug-
gest that the brain immune response determined by
genetic environment could be a potent disease modifier of
neurofibrillary degeneration. Whereas tau neurofibrillary
degeneration correlates with disease progression, neuroin-
flammation seems to regulate the resistance or susceptibil-
ity to neurodegeneration.
When the victim becomes the wrongdoer:
misfolded tau as a potent activator of the brain’s
immune response
It has been hypothesized that endogenous intracellular
tau may be released into the extracellular space upon
neuron degeneration [59]. However, very recent data
indicate that tau could be released into the brain inter-
stitial fluid (ISF) in the absence of neurodegeneration.
Moreover, the concentration of tau can be significantly
higher in the ISF than in the cerebrospinal fluid [60].
These findings strongly point out that intracellular tau
is released into the brain’s extracellular environment.
Numerous researchers have claimed that soluble
extracellular tau may promote neurotoxicity [59,61,62],
increase intracellular calcium through neuronal M1 and
M3 muscarinic receptors [61], cause synaptic impair-
ment [63] and induce blood-brain barrier damage [64].
We have recently found that misfolded truncated tau is
able to activate the innate immune response via MAPK
pathways. We reported that purified recombinant solu-
ble truncated tau caused the release of NO, proinflam-
matory cytokines (IL-1b,I L - 6a n dT N F - a)a n dt i s s u e
inhibitor of metalloproteinase 1 from mixed astroglia-
microglia cultures [65]. It is important to note that the
active concentration of misfolded tau was in the range
of 0.1 and 1 μM. Similarly, other disease-modified neu-
ronal proteins such as Ab and a-synuclein are able to
activate microglial cells in the same concentration range
(Ab 0.2 to 1 μM and a-synuclein 0.1 to 1 μM) [66-70].
Transcriptomic analysis revealed that truncated tau
increased mRNA levels of three MAPKs: c-Jun N-terminal
kinase, extracellular-signal-regulated kinase 1 and p38b,
which in turn led to the activation of transcription factors
such as activator protein 1 and NF-B. The activation of
transcription factors ultimately resulted in enhanced
expression of IL-1b,I L - 6 ,T N F - a and NO [65]. These
results, together with previously published data, demon-
strate that misfolded tau protein is able to induce an
innate immune response through a MAPK pathway and
that simultaneously tau’s pathological transformation can
be regulated by activated glial cells via the same pathway.
Conclusions
On the basis of our current body of knowledge, we can
conclude that neuroinflammation is a potent modifier of
the tau neurodegenerative cascade and, to some extent,
can determine the vulnerability of the brain to AD neu-
rodegeneration. The inflammatory response can affect
the tau pathological metamorphosis, increasing tau
phosphorylation via MAPK kinase pathways and acceler-
ating tangle formation. Extracellular tau can induce
immune responses via a MAPK kinase pathway as well
(Figure 4). Taken together, these results suggest that tau
is located at the crossroad of the neurodegenerative and
neuroinflammatory cascades. This is the reason to
believe that targeted immunomodulatory therapeutic
approaches can significantly modify the tau neurodegen-
erative cascade and may ultimately have a direct impact
on the clinical course of AD.
Abbreviations
IL: interleukin; NF-κB: nuclear factor κB; TNF-α: tumour necrosis factor α.
Acknowledgements
This work was supported by Axon Neuroscience and research grants VEGA
2/0144/08, VEGA 2/0067/10, LPP-0039-09 and APVV 0631-07.
Author details
1Institute of Neuroimmunology, 84510 Bratislava, Slovak Republic.
2Axon
Neuroscience GmbH, 1030 Vienna, Austria.
3Small Animals Clinic, University
of Veterinary Medicine and Pharmacy, Komenskeho 73, 041 81 Kosice,
Slovakia.
Authors’ contributions
NZ, ZK, SJ, OB, AM and PN each wrote the individual sections in sequential
order in the manuscript. DO created all the figures and illustrations. MN
coordinated all efforts, made decisions about content and shaped the final
form of the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 October 2011 Accepted: 7 March 2012
Published: 7 March 2012
References
1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM:
Microtubule-associated protein tau: a component of Alzheimer paired
helical filaments. J Biol Chem 1986, 261:6084-6089.
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI:
Abnormal phosphorylation of the microtubule-associated protein tau
(tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986,
83:4913-4917.
Zilka et al. Journal of Neuroinflammation 2012, 9:47
http://www.jneuroinflammation.com/content/9/1/47
Page 7 of 93. Glenner GG, Wong CW: Alzheimer’s disease and Down’s syndrome:
sharing of a unique cerebrovascular amyloid fibril protein. Biochem
Biophys Res Commun 1984, 122:1131-1135.
4. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R,
Walker JE, Milstein C, Roth M, Klug A: Isolation of a fragment of tau
derived from the core of the paired helical filament of Alzheimer
disease. Proc Natl Acad Sci USA 1988, 85:4506-4510.
5. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA:
Structural characterization of the core of the paired helical filament of
Alzheimer disease. Proc Natl Acad Sci USA 1988, 85:4884-4888.
6. Braak H, Braak E: Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991, 82:239-259.
7. Dickson DW: Neuropathological diagnosis of Alzheimer’s disease: a
perspective from longitudinal clinicopathological studies. Neurobiol Aging
1997, 18(4 Suppl):S21-S26.
8. Iqbal K, Grundke-Iqbal I: Alzheimer’s disease, a multifactorial disorder
seeking multitherapies. Alzheimers Dement 2010, 6:420-424.
9. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K: Cell mediators of
inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord
2000, 14:47-53.
10. Mrak RE, Griffin WS: The role of activated astrocytes and of the
neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease.
Neurobiol Aging 2001, 22:915-922.
11. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJM, van Gool W,
Hoozemans J: The significance of neuroinflammation in understanding
Alzheimer’s disease. J Neural Transm 2006, 113:1685-1695.
12. Walsch S, Aisen P: Inflammatory processes in Alzheimer’s disease. Expert
Rev Neurotherapeutics 2004, 4:793-798.
13. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG: Ferritin
is a component of the neuritic (senile) plaque in Alzheimer dementia.
Acta Neuropathol 1990, 81:105-110.
14. Sheffield LG, Marquis JG, Berman NE: Regional distribution of cortical
microglia parallels that of neurofibrillary tangles in Alzheimer’s disease.
Neurosci Lett 2000, 285:165-168.
15. Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P, Alafuzoff I:
Reactive microglia in aging and dementia: an immunohistochemical
study of postmortem human brain tissue. Acta Neuropathol 1999,
97:383-392.
16. Sheng JG, Mrak RE, Griffin WS: Glial-neuronal interactions in Alzheimer
disease: progressive association of IL-1α
+ microglia and S100β
+
astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol
1997, 56:285-290.
17. Cras P, Kawai M, Siedlak S, Perry G: Microglia are associated with the
extracellular neurofibrillary tangles of Alzheimer disease. Brain Res 1991,
558:312-314.
18. DiPatre PL, Gelman BB: Microglial cell activation in aging and Alzheimer
disease: partial linkage with neurofibrillary tangle burden in the
hippocampus. J Neuropathol Exp Neurol 1997, 56:143-149.
19. Probst A, Ulrich J, Heitz PU: Senile dementia of Alzheimer type: astroglial
reaction to extracellular neurofibrillary tangles in the hippocampus: an
immunocytochemical and electron-microscopic study. Acta Neuropathol
1982, 57:75-79.
20. McGeer PL, Akiyama H, Itagaki S, McGeer EG: Immune system response in
Alzheimer’s disease. Can J Neurol Sci 1989, 16(4 Suppl):516-527.
21. Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, Goux WJ, Lee V,
Johnson GV, Webster SD, Cooper NR, Bradt B, Rogers J: Complement
activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett
2001, 305:165-168.
22. Schwab C, Steele JC, McGeer PL: Neurofibrillary tangles of Guam
parkinson-dementia are associated with reactive microglia and
complement proteins. Brain Res 1996, 707:196-205.
23. Ishizawa K, Dickson DW: Microglial activation parallels system
degeneration in progressive supranuclear palsy and corticobasal
degeneration. J Neuropathol Exp Neurol 2001, 60:647-657.
24. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ:
In vivo imaging of microglial activation with [
11C](R)-PK11195 PET in
progressive supranuclear palsy. Mov Disord 2006, 21:89-93.
25. Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K,
Brooks DJ: In vivo imaging of microglial activation with [
11C](R)-
PK11195 PET in corticobasal degeneration. Mov Disord 2004,
19:1221-1226.
26. Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW, Neumaier B,
Ludolph AC, Reske SN, Landwehrmeyer GB: Imaging of activated microglia
with PET and [
11C]PK11195 in corticobasal degeneration. Mov Disord
2004, 19:817-821.
27. Paulus W, Bancher C, Jellinger K: Microglial reaction in Pick’s disease.
Neurosci Lett 1993, 161:89-92.
28. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG:
Induction of inflammatory mediators and microglial activation in mice
transgenic for mutant human P301S tau protein. Am J Pathol 2004,
165:1643-1652.
29. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J,
Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation
precede tangles in a P301S tauopathy mouse model. Neuron 2007,
53:337-351.
30. Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T,
Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H, Ishiguro K, Hasegawa M,
Yen SH, Chishti MA, Harigaya Y, Abe K, Okamoto K, St George-Hyslop P,
Westaway D: Accumulation of filamentous tau in the cerebral cortex of
human tau R406W transgenic mice. Am J Pathol 2005, 166:521-531.
31. Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H,
Westaway D, George-Hyslop PS, Shoji M, Nakazato Y: Microglial activation
in brain lesions with tau deposits: comparison of human tauopathies
and tau transgenic mice TgTau
P301L. Brain Res 2008, 1214:159-168.
32. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M: Human
misfolded truncated tau protein promotes activation of microglia and
leukocyte infiltration in the transgenic rat model of tauopathy. J
Neuroimmunol 2009, 209:16-25.
33. Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M: Genetic
background modifies neurodegeneration and neuroinflammation driven
by misfolded human tau protein in rat model of tauopathy: implication for
immunomodulatory approach to Alzheimer’sd i s e a s e .J Neuroinflammation
2010, 7:64.
34. Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M: First
transgenic rat model developing progressive cortical neurofibrillary
tangles. Neurobiol Aging , doi:10.1016/j.neurobiolaging.2010.10.015.
35. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G,
Kontsekova E, Novak M: Truncated tau from sporadic Alzheimer’s disease
suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006,
580:3582-3588.
36. Mackenzie IRA: Anti-inflammatory drugs and Alzheimer-type pathology in
aging. Neurology 2000, 54:732-734.
37. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological,
animal model and clinical studies. Neurobiol Aging 2007, 28:639-647.
38. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents
as possible protective factors for Alzheimer’s disease: a review of 17
epidemiologic studies. Neurology 1996, 47:425-432.
39. Zandi PP, Breitner JC: Do NSAIDs prevent Alzheimer’s disease? And, if so,
why? The epidemiological evidence. Neurobiol Aging 2001, 22:811-817.
40. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF,
Farlow MR, Sano M, Grundman M, Thal LJ: A randomized controlled trial
of prednisone in Alzheimer’s disease: Alzheimer’s Disease Cooperative
Study. Neurology 2000, 54:588-41.
41. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR,
Jin S, Thomas RG, Thal LJ: Alzheimer’s disease cooperative study: effects
of rofecoxib or naproxen vs placebo on Alzheimer disease progression:
a randomized controlled trial. JAMA 2003, 289:2819-2826.
42. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA,
Baranak CC: Rofecoxib protocol 091 study group: rofecoxib: no effect on
Alzheimer’s disease in a 1-year, randomized, blinded, controlled study.
Neurology 2004, 62:66-71.
43. de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M,
Borm G, Kremer B: No effect of one-year treatment with indomethacin
on Alzheimer’s disease progression: a randomized controlled trial. PLoS
One 2008, 3:e1475.
44. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC,
Montine TJ: Nonsteroidal anti-inflammatory drugs are associated with
increased neuritic plaques. Neurology 2010, 75:1203-1210.
45. Beeri MS, Schmeidler J, Lesser GT, Maroukian M, West R, Leung S,
Wysocki M, Perl DP, Purohit DP, Haroutunian V: Corticosteroids, but not
NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol
Aging , doi:10.1016/j.neurobiolaging.2011.02.011.
Zilka et al. Journal of Neuroinflammation 2012, 9:47
http://www.jneuroinflammation.com/content/9/1/47
Page 8 of 946. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL: Dystrophic microglia in the
aging human brain. Glia 2004, 45:208-212.
47. Streit WJ: Microglial senescence: does the brain’s immune system have
an expiration date? Trends Neurosci 2006, 29:506-510.
48. Streit WJ, Braak H, Xue QS, Bechmann I: Dystrophic (senescent) rather
than activated microglial cells are associated with tau pathology and
likely precede neurodegeneration in Alzheimer’s disease. Acta
Neuropathol 2009, 118:475-485.
49. Li Y, Liu L, Barger SW, Griffin WS: Interleukin-1 mediates pathological
effects of microglia on tau phosphorylation and on synaptophysin
synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci
2003, 23:1605-1611.
50. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB: Interleukin-6
induces Alzheimer-type phosphorylation of tau protein by deregulating
the cdk5/p35 pathway. Exp Cell Res 2004, 295:245-257.
51. Saez TE, Pehar M, Vargas M, Barbeito L, Maccioni RB: Astrocytic nitric oxide
triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 2004,
18:275-280.
52. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN,
Dickey CA, Morgan D: LPS-induced inflammation exacerbates phospho-
tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56.
53. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM:
Lipopolysaccharide-induced inflammation exacerbates tau pathology by
a cyclin-dependent kinase 5-mediated pathway in a transgenic model of
Alzheimer’s disease. J Neurosci 2005, 25:8843-8853.
54. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM,
Lamb BT: Regulation of tau pathology by the microglial fractalkine
receptor. Neuron 2010, 68:19-55.
55. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S,
LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ: Chronic neuron-specific
tumor necrosis factor-α expression enhances the local inflammatory
environment ultimately leading to neuronal death in 3 × Tg-AD mice.
Am J Pathol 2008, 173:1768-1782.
56. Gorlovoy P, Larionov S, Pham TTH, Neumann H: Accumulation of tau
induced in neurites by microglial proinflammatory mediators. FASEB J
2009, 23:2502-2513.
57. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT:
CX3CR1 deficiency alters microglial activation and reduces β-amyloid
deposition in two Alzheimer’s disease mouse models. Am J Pathol 2010,
177:2549-2562.
58. Ryman D, Lamb BT: Genetic and environmental modifiers of Alzheimer’s
disease phenotypes in the mouse. Curr Alzheimer Res 2006, 3:465-473.
59. Gómez-Ramos A, Díaz-Hernández M, Cuadros R, Hernández F, Avila J:
Extracellular tau is toxic to neuronal cells. FEBS Lett 2006, 580:4842-4850.
60. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI,
Mandelkow EM, Diamond MI, Lee VM, Holtzman DM: In vivo microdialysis
reveals age-dependent decrease of brain interstitial fluid tau levels in
P301S human tau transgenic mice. J Neurosci 2011, 31:13110-13117.
61. Gómez-Ramos A, Díaz-Hernández M, Rubio A, Miras-Portugal MT, Avila J:
Extracellular tau promotes intracellular calcium increase through M1 and
M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 2008,
37:673-681.
62. Gómez-Ramos A, Díaz-Hernández M, Rubio A, Díaz-Hernández JI, Miras-
Portugal MT, Avila J: Characteristics and consequences of muscarinic
receptor activation by tau protein. Eur Neuropsychopharmacol 2009,
19:708-717.
63. Moe JG, Chatterjee I, Davidowitz EJ, Arancio O: Modulation of synaptic
function by extracellular tau enriched in oligomers [abstract]. Alzheimers
Dement 2009, 5(4 Suppl):P499.
64. Kovac A, Zilkova M, Deli MA, Zilka N, Novak M: Human truncated tau is
using a different mechanism from amyloid-β to damage the blood-brain
barrier. J Alzheimers Dis 2009, 18:897-906.
65. Kovac A, Zilka N, Kazmerova Z, Cente M, Zilkova M, Novak M: Misfolded
truncated protein τ induces innate immune response via MAPK
pathway. J Immunol 2011, 187:2732-2739.
66. Paresce DM, Ghosh RN, Maxfield FR: Microglial cells internalize aggregates
of the Alzheimer’s disease amyloid β-protein via a scavenger receptor.
Neuron 1996, 17:553-565.
67. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H: IL-4-induced
selective clearance of oligomeric -amyloid peptide1-42 by rat primary
type 2 microglia. J Immunol 2008, 181:6503-6513.
68. Yang CN, Shiao YJ, Shie F, Guo BS, Chen PH, Cho CY, Chen YJ, Huang FL,
Tsay HJ: Mechanism mediating oligomeric Aβ clearance by naïve primary
microglia. Neurobiol Dis 2011, 42:221-230.
69. Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R,
Gendelman HE: Ion channel blockade attenuates aggregated α synuclein
induction of microglial reactive oxygen species: relevance for the
pathogenesis of Parkinson’s disease. J Neurochem 2007, 100:503-519.
70. Park JY, Paik SR, Jou I, Park SM: Microglial phagocytosis is enhanced by
monomeric α-synuclein, not aggregated α-synuclein: implications for
Parkinson’s disease. Glia 2008, 56:1215-1223.
doi:10.1186/1742-2094-9-47
Cite this article as: Zilka et al.: Who fans the flames of Alzheimer’s
disease brains? Misfolded tau on the crossroad of neurodegenerative
and inflammatory pathways. Journal of Neuroinflammation 2012 9:47.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zilka et al. Journal of Neuroinflammation 2012, 9:47
http://www.jneuroinflammation.com/content/9/1/47
Page 9 of 9